The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2018 | PALB2 predicts poor prognosis in AML and indicates potential targets for synthetic lethal therapies
Giovanni Martinelli, MD, of the Istituto Scientifico Romagnolo, Meldola, Italy, discusses his group’s investigation of the DNA damage repair gene, partner and localizer of BRCA2 (PALB2) in acute myeloid leukemia (AML). This is the first time this gene, which is well characterized in breast cancer, has been associated with AML, and they found higher expression of PALB2 predicted a poorer prognosis in patients. Interestingly, this opens up the question of the potential for PARP inhibitors in certain AML groups. This interview took place at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
